HC Bioscience Appoints Simon Tsang, Ph.D., as Chief Business Officer
Slice of Healthcare Team
09/11/2024
Key Highlights
- HC Bioscience appoints Simon Tsang, Ph.D., as Chief Business Officer.
- Dr. Tsang to spearhead business development initiatives for tRNA-based therapies.
- He brings over 20 years of experience in biotech and business development.
- HC Bioscience advances novel treatments for Hemophilia, Duchenne muscular dystrophy, and cancer.
Source: Business Wire
Notable Quotes
“ Simon’s combination of business acumen and scientific knowledge is a tremendous asset to our team. His leadership will be critical as we advance our lead program in Hemophilia towards clinical trials and continue to develop groundbreaking treatments. ”
Leslie Williams, CEO and Founder at HC Bioscience
“ The team’s commitment and innovative approach to protein editing have the potential to treat a wide range of genetically defined diseases. I look forward to driving the strategic advancement of this new therapeutic modality. ”
Simon Tsang, Ph.D., Chief Business Officer at HC Bioscience
